Published in

JCO Global Oncology, 9, 2023

DOI: 10.1200/go.23.00111

Links

Tools

Export citation

Search in Google Scholar

Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

PURPOSE The post–COVID-19 funding landscape for cancer research globally has become increasingly challenging, particularly in resource-challenged regions (RCRs) lacking strong research ecosystems. We aimed to produce a list of priority areas for cancer research in countries with limited resources, informed by researchers and patients. METHODS Cancer experts in lower-resource health care systems (as defined by the World Bank as low- and middle-income countries; N = 151) were contacted to participate in a modified consensus-seeking Delphi survey, comprising two rounds. In round 1, participants (n = 69) rated predetermined areas of potential research priority (ARPs) for importance and suggested missing ARPs. In round 2, the same participants (n = 49) rated an integrated list of predetermined and suggested ARPs from round 1, then undertook a forced choice priority ranking exercise. Composite voting scores ( T-scores) were used to rank the ARPs. Importance ratings were summarized descriptively. Findings were discussed with international patient advocacy organization representatives. RESULTS The top ARP was research into strategies adapting guidelines or treatment strategies in line with available resources (particularly systemic therapy) ( T = 83). Others included cancer registries ( T = 62); prevention ( T = 52); end-of-life care ( T = 53); and value-based and affordable care ( T = 51). The top COVID-19/cancer ARP was strategies to incorporate what has been learned during the pandemic that can be maintained posteriorly ( T = 36). Others included treatment schedule interruption ( T = 24); cost-effective reduction of COVID-19 morbidity/mortality ( T = 19); and pandemic preparedness ( T = 18). CONCLUSION Areas of strategic priority favored by cancer researchers in RCRs are related to adaptive treatment guidelines; sustainable implementation of cancer registries; prevention strategies; value-based and affordable cancer care; investments in research capacity building; epidemiologic work on local risk factors for cancer; and combatting inequities of prevention and care access.